PROTOKINETIX BLOG

Find out how AAGP® is changing lives through cell survival

As we move forward with clinical research for our anti-aging glycopeptide, AAGP®, we continue to uncover new areas of opportunity for the molecule. See how AAGP® is helping to provide more hope for patients and investors in the areas of ophthalmology, transplants, dermatology and biomanufacturing.

May 02, 2016

byncaipen

Ophthalmology | Transplants

AAGP® Improves Results in Stem Cells Transplanted in Retina Tissue by 300%

St. Marys, West Virginia ProtoKinetix, Incorporated (OTCQB:PKTX) (the “Company” or “ProtoKinetix”) (www.protokinetix.com) is pleased to announce that a paper submitted by Dr. Kevin Gregory-Evans on ProtoKinetix’ AAGP® has been accepted...Read more

Request More Information

Talk to a member of the ProtoKinetix team to learn more about our research and results.